›› 2017, Vol. 39 ›› Issue (2): 198-201.doi: 10.16507/j.issn.1006-6055.2017.03.014

• 科技态势与趋势 • 上一篇    下一篇

间充质干细胞治疗缺血性脑血管病的研究现状

张金梅 杨远荣   

  1. 华中科技大学同济医学院附属荆州医院药学部,荆州434020
  • 收稿日期:2016-07-18 修回日期:2016-09-19 出版日期:2017-04-25 发布日期:2017-04-26
  • 基金资助:

    荆州市科技局项目( 2016097) 资助

Research Status in Treatment of Ischemic Cerebrovascular Diseases by Mesenchymal Stem Cells

  1. ZHANG Jinmei YANG Yuanrong
  • Received:2016-07-18 Revised:2016-09-19 Online:2017-04-25 Published:2017-04-26

摘要:

缺血性脑血管病是一种缺血性疾病,正逐渐成为全世界发病和致死的主要原因之一。在动物模型和临床试验中,间充质干细胞( MSCs) 已被用于缺血性脑血管病。大量研究表明,MSCs 的治疗是安全的,能改善缺血性疾病患者的症状,但其疗效与多种因素有关,其中包括细胞移植途径、移植时间窗和剂量及MSCs 的来源等。本文综述了这些影响因素及采用MSCs 治疗缺血性脑血管病的作用机制和临床试验的安全性,为进一步的研究和临床治疗提供帮助。

关键词:  , 间充质干细胞( MSCs) , 细胞治疗, 缺血性脑血管病, 细胞移植, 作用机制, 移植途径, 细胞移植时间窗

Abstract:

Ischemic cerebrovascular disease is one of ischemic diseases which is becoming a leading cause of morbidity and mortality in the whole world.Mesenchymal stem cells( MSCs) have been used to treat ischemic cerebrovascular diseases in animal models and clinical trials.Lots of publications demonstrated that MSCs therapy was safe and relieved symptoms of patients.However,many factors may influence therapeutic efficacy including transplantation route,time window,dose and source of MSCs.In this paper,all these factors as well as mechanisms of MSCs-based therapeutics for ischemic cerebrovascular and clinical trials safety are reviewed.It will provide help for further research and clinical treatment.

Key words: Mesenchymal stem cells( MSCs) , cell therapy, ischemic cerebrovascular diseases, cell transplantation, mechanism, transplantation route, time window for cell transplantation

中图分类号: